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AbstrAct
Objective Oesophageal cancer is the seventh most 
common cause of cancer-related death worldwide. 
Disease relapse is frequent and treatment options are 
limited.
Design To identify new biomarker-defined therapeutic 
approaches for patients with oesophageal cancer, we 
integrated the genomic profiles of 17 oesophageal 
tumour-derived cell lines with drug sensitivity data 
from small molecule inhibitor profiling, identifying drug 
sensitivity effects associated with cancer driver gene 
alterations. We also interrogated recently described RNA 
interference screen data for these tumour cell lines to 
identify candidate genetic dependencies or vulnerabilities 
that could be exploited as therapeutic targets.
results By integrating the genomic features of 
oesophageal tumour cell lines with siRNA and drug 
screening data, we identified a series of candidate 
targets in oesophageal cancer, including a sensitivity 
to inhibition of the kinase BTK in MYC amplified 
oesophageal tumour cell lines. We found that this 
genetic dependency could be elicited with the clinical 
BTK/ERBB2 kinase inhibitor, ibrutinib. In both MYC and 
ERBB2 amplified tumour cells, ibrutinib downregulated 
ERK-mediated signal transduction, cMYC Ser-62 
phosphorylation and levels of MYC protein, and elicited 
G1 cell cycle arrest and apoptosis, suggesting that this 
drug could be used to treat biomarker-selected groups of 
patients with oesophageal cancer.
conclusions BTK represents a novel candidate 
therapeutic target in oesophageal cancer that can be 
targeted with ibrutinib. On the basis of this work, a 
proof-of-concept phase II clinical trial evaluating the 
efficacy of ibrutinib in patients with MYC and/or ERBB2 
amplified advanced oesophageal cancer is currently 
underway (NCT02884453).
trial registration number NCT02884453; Pre-results
IntrODuctIOn
Oesophageal carcinoma is the seventh leading cause 
of cancer-related mortality and represents an area of 
unmet clinical need.1 Over 450 000 people world-
wide are affected with this disease, and the incidence 
of oesophageal adenocarcinoma (EAC) continues 
to rise rapidly, although oesophageal squamous cell 
carcinoma (ESCC) is the most common histology.2 
Integrated genomic characterisation of oesophageal 
carcinoma has revealed a separation between EAC 
and ESCC. This is demonstrated by a closer resem-
blance of genomic sequencing data from ESCC with 
squamous cell carcinomas of other anatomical sites 
than when compared with genomic profiles from 
primary EAC.3 EAC and ESCC are also distinct in 
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significance of this study
What is already known on this subject?
 ► Oesophageal cancer is the seventh leading 
cause of cancer-related mortality and 
represents an area of unmet clinical need.
 ► Additional targeted approaches to treating this 
disease are urgently required, particularly in 
patients who progress after first-line therapy.
 ► Genomic profiling of oesophageal cancers has 
highlighted the presence of amplifications 
in oncogenes including CCND1, ERBB2 and 
MYC, and efforts are required to exploit this 
information to identify therapeutic targets 
that could be used to treat biomarker-selected 
groups of patients with oesophageal cancer
What are the new findings?
 ► By analysing large-scale in vitro functional 
genomic profiling data and drug data from 
tumour cell models of oesophageal cancer 
and integrating this with genomic profiling of 
these models, we have identified a series of 
candidate genetic vulnerabilities associated 
with cancer driver gene alterations common in 
oesophageal cancers.
 ► One of the most profound effects identified 
was an addiction to the kinase BTK in 
MYC amplified oesophageal tumour cells, 
which could be elicited with the kinase 
inhibitor ibrutinib and which also targeted 
oesophageal tumour cells with ERBB2 
amplification.
How might it impact on clinical practice in the 
foreseeable future?
 ► As the result of the observations made in this 
study, a proof-of-concept phase II clinical trial 
evaluating the efficacy of ibrutinib in patients 
with MYC and/or ERBB2 amplified advanced 
oesophageal cancer is currently underway 
(NCT02884453).
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terms of their aetiology in that EAC may originate from Barrett’s 
oesophagus, a premalignant condition that arises as a compli-
cation of chronic gastro-oesophageal reflux disease,4 whereas 
ESCC does not. Overall, 5-year survival rates over the past 30 
years have improved from 5% to 19%. However, the prog-
nosis for patients diagnosed with oesophageal cancer remains 
poor.5 6 Patients with EAC frequently present with advanced, 
inoperable disease, but even in those patients with operable 
disease the frequency of disease recurrence after surgery remains 
high.2 Treatment options for patients with oesophageal cancers 
are extremely limited. Platinum-based chemotherapy remains 
the mainstay of treatment for EAC in the perioperative and 
metastatic setting,7–11 and although taxanes and camptothecin 
analogues have been introduced into treatment regimens, these 
have not delivered large improvements in median survival.12–14 
A small number of targeted therapeutic approaches exist for 
patients with EAC; these include the antivascular endothelial 
growth factor receptor 2 (anti-VEGFR2) therapeutic antibody 
ramucirumab, used in patients who progress after fluoropyrimi-
dine or platinum-containing chemotherapy,15 16 and the Erb-B2 
receptor tyrosine kinase (ERBB2) antibody, trastuzumab, used 
in combination with platinum-based chemotherapy as a first-
line therapy in patients whose tumours exhibit ERBB2 oncogene 
amplification and/or overexpression.17 However, there are no 
licensed targeted therapies for patient with ESCC. Therefore, 
there is a clear need to identify additional targeted approaches to 
treating this disease, particularly in those patients who progress 
after first-line therapy.
One approach to this problem has been to define the molec-
ular make-up of the disease, with the ultimate aim of using this 
information to inform the design of novel biomarker-strati-
fied therapeutic approaches. For example, genomic profiling 
of oesophageal cancers has defined the mutational landscape 
of the disease.3 18–24 This work has highlighted the presence of 
a number of recurrent somatically occurring mutations in the 
disease, including amplifications of several well-known onco-
genes including cyclin D1 (CCND1 15% in EAC3 and 46% in 
ESCC23), ERBB2 (32% in EAC3 and up to 11% in ESCC25) and 
MYC (32% in EAC and 23% in ESCC3). Building on this work, 
efforts are now required to exploit this information to identify 
therapeutic targets that could be used to treat biomarker-selected 
groups of patients with oesophageal cancer. Here, we describe 
an analysis of large-scale in vitro functional genomic profiling of 
tumour cell models of oesophageal cancer. Integrating this func-
tional profiling with genomic profiling of these models, we iden-
tify a series of candidate genetic vulnerabilities associated with 
cancer driver gene alterations common in oesophageal cancers. 
One of the most profound effects identified in this way was 
an addiction to the kinase BTK in MYC amplified oesophageal 
tumour cells; this addiction could be exploited with the kinase 
inhibitor ibrutinib, which also targeted oesophageal tumour cells 
with ERBB2 amplification, suggesting a novel candidate thera-
peutic approach in EAC and ESCC.
results
Identification of genetic dependencies in oesophageal 
tumour cell lines that are associated with cancer driver gene 
alterations
We aimed to identify genetic dependencies (GD) (ie, gene addic-
tion and synthetic lethal effects) in oesophageal cancer that are 
associated with the presence of alterations in known oncogenic 
driver genes. To do this, we (1) compiled copy number and 
mutation profiles of 17 oesophageal tumour-derived cell lines 
using array comparative genomic hybridisation (aCGH) and 
exome sequencing data; (2) used these data to classify tumour 
cell lines according to the presence or absence of alterations in 
specific cancer driver genes, and then (3) interrogated recently 
described RNA interference (RNAi) screen data for the same 
tumour cell lines26 to identify RNAi reagents that selectively 
targeted oesophageal tumour cell lines with cancer driver gene 
alterations. In addition, we carried out small molecule inhib-
itor drug sensitivity profiling in the same oesophageal tumour 
cell line panel, and by integrating these data with the genomic 
profiles of the tumour cell lines identified drug sensitivity 
effects associated with alterations in specific cancer driver genes 
(figure 1A).
Genomic profiling of oesophageal tumour cell lines
We selected 17 tumour cell lines, eight of which were derived from 
EAC (OE19, OE33, OACP4C, FLO-1, SK-GT-4, KYAE-1, ESO26 
and JH-EsoAd1) and nine of which were derived from ESCC 
(KYSE70, TE1, TE5, TE6, TE8, TE9, TE10, TE11 and TE14; 
table 1). We used in-house aCGH data (32K based array CGHarray 
platform27) and publicly available single nucleotide polymorphism 
genotyping data (http:// cancer. sanger. ac. uk/ cosmic, https:// portals. 
broadinstitute. org/ ccle/ home; online supplementary tables 1–17) 
to determine the copy number profile of each tumour cell line and 
used publicly available exome sequencing data to identify coding 
sequence variants in each model. We then cross-referred these 
tumour cell line genomic profiles to those from primary oesopha-
geal tumours3 21 23 24 28–34 to annotate tumour cell lines in the panel 
according to the presence or absence of mutations in genes known 
to be recurrently mutated, amplified or deleted in primary oesoph-
ageal tumours. Cancer driver genes harbouring coding mutations 
or copy number alterations in two or more oesophageal tumour 
cell lines are illustrated in figure 1B and online supplementary table 
18.
Consistent with the mutational spectrum of the clinical disease, 
we found that mutations in genes such as TP53 (mutated in 72% of 
primary EAC19 and 83% of ESCC23) were highly prevalent in the 
oesophageal tumour cell line panel. Six cell lines (OE19, OACP4C, 
SK-GT-4, KYSE70, TE9 and TE14) were predicted to have prema-
ture truncating TP53 mutations and 11 cell lines were predicted to 
have missense TP53 mutations (OE33, FLO-1, KYAE-1, ESO26, 
JHEsoAd1, TE1, TE5, TE6, TE8, TE10 and TE11). The SYNE1 
gene (spectrin repeat containing nuclear envelope protein 1 gene), 
mutated in approximately 25% of primary treatment-naïve EAC 
tumours,19 was mutated in six oesophageal cell lines (FLO-1, 
KYAE-1, KYSE70, TE5, TE9 and TE10). Nine out of the 17 
oesophageal tumour cell lines harboured homozygous copy number 
deletion of CDKN2A (cyclin-dependent kinase inhibitor 2A, p16/
p14 gene), found to be deleted in 76% of EAC and ESCC of the 
oesophagus.3 In addition, 35% of the tumour cell line panel exhib-
ited ERBB2 amplification events, a frequency comparable to the 
ERBB2 amplification rate in primary EACs.3 Furthermore, amplifi-
cation of CCND1 (Cyclin D1 gene) was present in seven oesopha-
geal models (JHEsoAd1, TE6, TE8, TE9, TE10, TE11 and TE14), 
and MYC amplification was present in five oesophageal cancer 
cell lines (OACP4C, KYAE-1, TE8, TE9 and TE10); in the clinical 
disease CCND1 amplification events are found in 15% of primary 
EAC3 and 46% of primary ESCC23 cases, whereas MYC is amplified 
in 23% in EAC and 32% in ESCC.3 In total, we identified 35 genes 
that were recurrently mutated in primary oesophageal tumours that 
were also mutated in at least 3 out of 17 oesophageal tumour cell 
line models.
group.bmj.com on August 29, 2017 - Published by http://gut.bmj.com/Downloaded from 
3Chong IY, et al. Gut 2017;0:1–13. doi:10.1136/gutjnl-2017-314408
Figure 1 Identifying candidate genetic dependencies in oesophageal tumour cell lines. (A) Schematic of compilation of genomic profiles of 17 
oesophageal tumour-derived cell lines using array comparative genomic hybridisation and exome sequencing. Oesophageal tumour cell lines were 
classified according to histology (SCC vs EAC) and cancer driver alterations. The 17 oesophageal cancer cell lines were screened in 384-well plate 
format using a small molecule drug library of compounds in late drug development or clinical trials. These drug data and high-throughput siRNA 
screening data (714 siRNA targeting kinase and kinase related genes26) from the same cell lines were interrogated and integrated with histological 
and cancer driver alterations to identify drug or siRNA sensitivities associated with SCC or EAC histology and cancer driver mutations. (B) Graph 
annotating predicted DNA coding mutations and copy number alterations present in two or more of 17 oesophageal cancer cell lines (8 EAC and 
9 SCC) that are also to be found recurrently mutated in primary oesophageal tumours. aCGH, array comparative genomic hybridisation; EAC, 
oesophageal adenocarcinoma; SCC, squamous cell carcinoma.
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small molecule drug sensitivity profiling and integration with 
genomic profiles of oesophageal tumour cell lines
Using a 384-well plate screening approach, we assessed the sensi-
tivity of each oesophageal tumour cell line to an in-house curated 
library of 80 drugs that are currently used for the treatment of 
cancer or which are in late-stage development (online supple-
mentary table 19). Each drug in this library was present in 
four different concentrations (1, 10, 100 and 1000 nM). Each 
tumour cell line was plated in 384-well plates containing tissue 
culture media plus library small molecules and then cultured for 
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table 1 Oesophageal tumour cell lines used for high-throughput 
siRNA and drug screening
cell line Histology
  OE19 EAC
  OE33 EAC
  OACP4C EAC
  FLO-1 EAC
  SK-GT4 EAC
  KYAE-1 EAC
  ESO26 EAC
  JH-EsoAd1 EAC
  KYSE70 SCC
  TE1 SCC
  TE5 SCC
  TE6 SCC
  TE8 SCC
  TE9 SCC
  TE10 SCC
  TE11 SCC
  TE14 SCC
EAC, oesophageal adenocarcinoma; SCC, squamous cell carcinoma.
upper GI cancer
a further 5 days, at which point cell viability was estimated using 
CellTiter-Glo reagent (figure 2A). Each tumour cell line was 
screened in triplicate, with 15 of the 17 tumour cell lines gener-
ating highly reproducible data (median correlation coefficients 
of >0.9 between replicates; online supplementary figure 1) and 
suitable dynamic range quality control criteria (estimated by Z′ 
calculations). The cell viability measurements for each drug titra-
tion (online supplementary table 19) were used to generate area 
under the curve (AUC) dose response data for each tumour cell 
line, illustrated as a heatmap in figure 2A and in online supple-
mentary table 20.
We found the vast majority of oesophageal tumour cell lines to 
be sensitive to conventional cytotoxic agents including gemcit-
abine, camptothecin and paclitaxel, as well as the HSP90 inhib-
itor 17-AAG, the polo-like kinase 1 (PLK1) inhibitor BI2536, 
the cyclin-dependent kinase modulator flavopiridol and the 
P21 activated kinase 4 inhibitor, PF03758309 (figure 2A and 
online supplementary table 20). We then assessed if drug sensi-
tivity effects differed according to whether tumour cell lines 
were derived from EAC or ESCC (online supplementary table 
21) and found that ESCC cell lines were more sensitive to four 
drugs including dasatinib (p=0.032, median permutation (MP), 
t-test, figure 2B), a multitarget tyrosine kinase inhibitor and Src 
family tyrosine kinase inhibitor, and BI2536 (p=0.033, MP 
test, figure 2C), a small molecule inhibitor of PLK1. Compared 
with EAC cell lines, the ESCC cell lines were more sensitive to 
the epidermal growth factor receptor (EGFR) small molecule 
inhibitor, gefitinib (p=0.034, MP test, figure 2D), a finding that 
was consistent with data from a subgroup analysis of the cancer 
oesophagus gefitnib (COG) trial that revealed an HR in favour 
of gefitinib treatment in patients with ESCC.35 In addition, 
ESCC cell lines were found to be more sensitive to the pan-ErbB 
inhibitor, canertinib (p=0.038, MP test, figure 2E), compared 
with EAC cell lines.
We integrated the data from the small molecule inhibitor screen 
with the genomic profiles of the tumour cell line panel to iden-
tify drug sensitivity effects associated with likely cancer driver 
gene alterations (figure 1A, online supplementary table 22). As 
expected, this analysis indicated that ERBB2 or EGFR amplified 
tumour cell lines were preferentially sensitive to the Erb-family 
kinase inhibitor lapatinib (p=0.038, Mann-Whitney U test, 
figure 2F), providing proof of principle that this approach could 
identify drug sensitivities associated with molecularly defined 
subgroups of oesophageal cancer. We also noted that oesopha-
geal tumour cell lines that harbour missense mutations predicted 
to result in amino acid changes in the PIK3CA helicase domain 
exhibited the greatest sensitivity to the PI3-kinase/AKT signal-
ling pathway inhibitor BEZ235 (p=0.018, MP test, figure 2G). 
Oesophageal tumour cell lines harbouring mutations within the 
PIK3CA helicase domain also exhibited preferential sensitivity 
to the 3-phosphoinositide-dependent protein kinase 1 inhibitor 
GSK-2334470A (p=0.021, MP test) and vinorelbine (p=0.032, 
MP test, figure 2H).
Integration of genomic profiles with sirnA data
Using a similar data integration scheme as for the drug sensi-
tivity data, we cross-referred the genomic profiles of the 
tumour cell line panel to in-house generated data describing 
the sensitivity of each of the 17 oesophageal tumour cell line 
models and an additional 103 tumour cell lines to siRNAs 
designed to target a panel of 714 genes encoding kinases 
and kinase-related proteins (the ‘Campbell et al data set’26) 
as a means to identify candidate GDs in oesophageal cancers 
(online supplementary figure 2 and supplementary table 23). 
As kinases represent a pharmacologically tractable family of 
enzymes, we reasoned that doing so might also identify targ-
etable vulnerabilities associated with molecularly defined 
subsets of the disease (figure 1A).
Initially, we used this integrated analysis to identify those 
kinases that when targeted with siRNA selectively targeted the 
oesophageal tumour cell lines, as opposed to the other 103 
tumour cell lines that we also profiled by siRNA screening in 
our data set.26 This analysis suggested that, compared with 
non-oesophageal tumour cell lines, those derived from oesopha-
geal cancers exhibited dependencies on NEK9 (p=0.00026, MP 
test), PACE1 (p=0.00027, MP test), MGC42105 (p=0.0003, 
MP test) and CDKN2C (p=0.00058, MP test) (figure 3A and 
online supplementary table 24). When ESCC-derived cell lines 
were compared with EAC-derived cell lines, we found EGFR 
to be the most profound GD associated with ESCC histology 
(p=0.000006, MP test, figure 3B and online supplementary 
table 25). This observation confirms the enhanced sensitivity of 
ESCC cell lines to the EGFR small molecule inhibitor, gefitinib, 
and the pan-ErbB inhibitor, canertinib, seen in the small mole-
cule drug screen (figure 2E). When using the genomic profiles 
of the oesophageal tumour cell lines to identify GD associated 
with alterations in specific cancer driver genes (online supple-
mentary table 26), we found that, as expected, siRNA designed 
to target ERBB2 itself preferentially targeted ERBB2 amplified 
oesophageal tumour cell lines (p=0.019, MP test, figure 3D,E), 
supporting the hypothesis that ERBB2 amplification can lead to 
an oncogene addiction effect.17 We found that ERBB2 amplified 
oesophageal tumour cell lines also exhibited GDs on members 
of the mitogen-activated protein kinase family that signal down-
stream of ERBB236 including MAPK2K2 (p=0.0073, MP test, 
figure 3D), MAP2K3 (p=0.0082, MP test, figure 3F) and MAPK6 
(p=0.0082, MP test, figure 3D).
MYC is amplified in 23% of EAC and 32% of ESCC.3 
We found MYC amplified oesophageal tumour cell lines to 
exhibit GDs on CLK1 (Cdc2-like kinase gene, p=0.02, MP 
test, figure 3G), BTK (Bruton agammaglobulinaemia tyrosine 
kinase gene, p=0.017 MP test, figure 3H), ALK (anaplastic 
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Figure 2 Small molecule drug sensitivity profiling and integration with genomic profiles of oesophageal tumour cell lines. (A) Heatmap displaying 
AUC measurements for each of the 80 small molecule inhibitors in the high-throughput drug screen and for each of the oesophageal cancer cell lines 
that passed quality control. Box and whisker plots of AUC values illustrating preferential sensitivity of SCC oesophageal cell lines to (B) dasatinib 
(p=0.032, MP test), (C) BI-2536 (p=0.033, MP test), (D) gefitinib (p=0.034, MP test) and (E) canertinib (p=0.038, MP test). (F) Box and whisker plots 
of AUC values illustrating preferential sensitivity of ERBB2 and EGFR amplified oesophageal cancer cell lines to lapatinib (p=0.038, Mann-Whitney 
U test). (G) Box and whisker plots of AUC values illustrating preferential sensitivity of oesophageal tumour cell lines harbouring PIK3CA mutations 
and BEZ235 (p=0.018, MP test) and (H) vinorelbine (p=0.032, MP test). AUC, area under the curve; MP, median permutation; SCC, squamous cell 
carcinoma.
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lymphoma receptor tyrosine kinase gene, p=0.008 MP 
test, figure 3I) and PRKCA (protein kinase C alpha gene, 
p=0.028 MP test, figure 3G). Among other GDs identified 
in this way, we observed a relationship between SMARCA4 
copy number loss and a GD on BRD4 (p=0.022, MP test, 
figure 3J,K), a member of the BET (bromodomain and extra 
terminal domain) family. CCND1 amplified oesophageal 
tumour cell lines exhibited GD on TYK2 (tyrosine kinase 
2) tyrosine kinases (figure 3L). Other GDs identified in the 
CCND1 amplified oesophageal tumour cell lines included 
FLT1 (which encodes VEGFR1, p=0.0054, MP test), ROCK1 
(rho-associated, coiled–coil-containing protein kinase gene, 
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Figure 3 Integration of genomic profiles with siRNA data. (A) Radar plot showing key genetic dependencies associated with oesophageal tumour 
cell lines compared with tumour cell lines from other histologies.26 The concentric circles indicate the degree of statistical significance and depth of 
colour indicates separation of Z scores. Radar plots showing key genetic dependencies associated with (B) oesophageal SCC histology and (C) EAC 
histology. (D) Radar plot showing key genetic dependencies associated with ERBB2 amplification. Box and whisker plots of Z score values showing 
that targeting of (E) ERBB2 (p=0.019, MP test) and (F) MAP2K3 (p=0.0082, MP test) is selectively lethal in ERBB2 amplified oesophageal cancer 
cell lines. (G) Radar plot showing key genetic dependencies associated with MYC amplification. (H) Box and whisker plots of Z score values showing 
that targeting of BTK (p=0.017, MP test) and (I) ALK (p=0.008, MP test) is selectively lethal in MYC amplified oesophageal cell lines. (J) Radar 
plot showing key genetic dependencies associated with copy number deletions in SMARCA4 in oesophageal cancer cell lines. (K) Box and whisker 
plots of Z score values showing that targeting BRD4 (p=0.022, MP test) is selectively lethal in oesophageal tumour cell lines harbouring SMARCA4 
copy number loss. (L) Radar plot showing key genetic dependencies associated with CCND1 amplification. (M) Box and whisker plots of Z score 
values showing that targeting ROCK1 (p=0.0056, MP test) is selectively lethal in CCND1 amplified oesophageal cancer cell lines. EAC, oesophageal 
adenocarcinoma; MP, median permutation; SCC, squamous cell carcinoma.
upper GI cancer
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p=0.0056 MP test, figure 3M) and TGFBR1 (TGFβ receptor1 
gene, p=0.013, MP test, figure 3L).
Ibrutinib sensitivity in MYc and erbb2 amplified oesophageal 
cancer
Analysis of the oesophageal kinase dependency profiles revealed 
that one of the most profound associations was between MYC 
amplification and sensitivity to BTK siRNA (p=0.017, MP test, 
figure 3H). Although BTK has been most studied within the 
context of B cell malignancies37 and comprises a key compo-
nent downstream of BCR signalling,38 BTK isoforms are also 
present in epithelial tumours including breast,39 prostate,40 
colon41 and gastric cancers.42 We assessed BTK protein and 
mRNA expression across the panel of oesophageal tumour cell 
lines and found that canonical BTK is expressed in these models, 
although at low levels (figure 4A,B). We also confirmed that a 
splice variant, BTK-C, is expressed in the oesophageal tumour 
models (figure 4C,D).
We validated the BTK/MYC synthetic lethal interaction in 
MYC amplified oesophageal tumour cell lines using multiple, 
different BTK-targeting siRNAs (figure 4E,F,G), suggesting 
that this was unlikely to be an off-target effect. In addition, we 
observed decreased cell viability (figure 4H) and a reduction 
of BTKC mRNA expression after transfection with individual 
siRNAs specifically targeting BTK-C (figure 4I and online supple-
mentary figure 3), suggesting that the BTK-C isoform is essen-
tial in oesophageal tumour models. To investigate whether 
small molecule inhibition of BTK could mimic these effects, we 
exposed the panel of oesophageal tumour cell lines to increasing 
concentrations (0.1–10 µM) of the clinical BTK inhibitor ibru-
tinib, a drug that has durable single-agent efficacy in relapsed 
mantle cell lymphoma, Waldenstrom’s macroglobulinaemia and 
chronic lymphocytic leukaemia.43 44 While ibrutinib is a potent 
BTK inhibitor, it also directly inhibits ERBB2.45 46 Consistent 
with this, our analysis of ibrutinib sensitivity in oesophageal 
tumour cell lines revealed that there was preferential sensitivity 
to ibrutinib in both MYC amplified and/or ERBB2 amplified 
oesophageal tumour cell lines (p=0.018, Mann-Whitney U test, 
figure 5A,B).
We wanted to examine the mechanism of ibrutinib sensi-
tivity in MYC amplified oesophageal cell lines. We found that 
MYC protein levels were reduced by ibrutinib exposure in both 
KYAE-1 (MYC amplified) and TE8 (MYC and ERBB2 ampli-
fied) oesophageal tumour cell lines (figure 5C,D). Transfection 
of siRNA targeting MYC confirmed that these tumour cell lines 
were addicted to MYC (figure 5E,F). Ibrutinib exposure also 
caused an increased G1 fraction in MYC amplified and MYC/
ERBB2 coamplified oesophageal tumour cell lines (figure 5G,H) 
but not in tumour cell lines without these amplification events 
(figure 5I). In MYC amplified and also MYC/ERBB2 coampli-
fied oesophageal tumour cell lines, ibrutinib exposure caused a 
reduction in phosphorylated Rb, total Rb and cyclin D1 protein 
levels (figure 5J,K) not seen in non-amplified tumour cell lines 
(figure 5L), consistent with the increased G1 fraction. Ibrutinib 
exposure also increased annexin V and cleaved PARP1 levels 
in sensitive tumour cells (figure 5M,N), suggesting that the G1 
arrest caused by ibrutinib might eventually drive an apoptotic 
response.
erK1/2 is downregulated by ibrutinib
BTK is known to signal via the ras/mitogen-activated protein 
kinase (RAS-RAF-MEK-ERK) pathway.41 To investigate whether 
this contributed to the ibrutinib-dependent reduction of MYC 
protein levels in oesophageal tumour cells, we evaluated changes 
in p-ERK protein expression after ibrutinib exposure. We 
observed a reduction in p-BTK (figure 6A), indicating decreased 
catalytic activity of BTK and p-ERK levels (figure 6B,C) after 
ibrutinib exposure. As ERK is a known mediator of MYC phos-
phorylation at serine 62,47 we assessed changes in p-MYC S62 
protein expression after exposure to ibrutinib and observed a 
decrease in p-MYC S62 levels in oesophageal tumour cell lines 
that were either MYC amplified or MYC/ERBB2 coamplified 
(figure 6D,E). Phosphorylated MYC at serine 62 (p-MYC S62) 
is required for stabilisation of MYC protein levels.48 Consis-
tent with this, we observed a reduction in MYC protein levels 
(figure 6D,E). Taken together, these results suggested that expo-
sure to ibrutinib resulted in a reduction in MYC in oesophageal 
tumour models by reduction of BTK-dependent, ERK-mediated, 
MYC phosphorylation.
DIscussIOn
In this study, we show how integration of functional genomic 
profiling data with genotypic data from oesophageal cancer 
tumour cell lines may be used to identify candidate GDs. By 
undertaking high-throughput small molecule drug screening, 
we provide a public resource for the identification of biomarker 
driven therapies in a disease that currently has very limited treat-
ment options.
By interrogating drug and siRNA data with copy number 
profiling data, we identified an addiction to BTK in MYC ampli-
fied oesophageal tumour cell line models that may represent an 
induced essentiality where the gain of MYC function induces a 
dependency on BTK.49 We exploited this addiction with the small 
molecule inhibitor ibrutinib that targets both BTK and ERBB2, 
and found increased sensitivity in MYC and/or ERBB2 ampli-
fied oesophageal tumour models to ibrutinib. Ibrutinib expo-
sure also resulted in downregulation of cMYC. Mechanistically, 
one model that is consistent with these data might be that BTK 
and ERBB2 inhibition with ibrutinib results in downregulation 
of cMYC, likely via deregulation of ERK signalling. The use of 
ibrutinib in this context exemplifies how molecular and func-
tional profiling data might be used to design novel therapeutic 
approaches for patients with oesophageal cancer.
Ibrutinib already has Food and Drug Administration approval 
for the treatment of patients with Waldenstrom’s macroglobu-
linaemia,50 mantle cell lymphoma44 and chronic lymphocytic 
leukaemia43 based on the demonstration of durable responses 
in single-arm multicentre clinical studies that enrolled patients 
with previously treated disease. Considering the known safety 
profile of ibrutinib, we have initiated a proof-of-concept 
single-arm phase II trial of ibrutinib in patients with advanced 
oesophagogastric cancer harbouring MYC and/or ERBB2 
amplifications (ibrutinib in MYC amplified oesophageal cancer 
(iMYC)trial — NCT NCT02884453) who have progressed 
after first-line treatment. Patients recruited to the iMYC trial 
undergo prescreening for MYC and ERBB2 amplification by 
fluoresence in situ hybridisation criteria. The role for ibrutinib 
in ERBB2 amplified EAC may be clinically relevant as there are 
currently no approved anti-ERBB2 therapies in the second-line 
setting; approximately half of patients with advanced EAC have 
de novo resistance to first-line trastuzumab, and the median 
time to progression following initial response to chemotherapy 
and trastuzumab is only 7.1 months.17 Exploratory molecular 
and functional imaging biomarker analyses have been incor-
porated into the iMYC trial where serial tumour biopsies and 
blood samples are retrieved at screening, during treatment and 
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Figure 4 BTK expression in oesophageal tumour cell lines. (A) Western blot showing expression of BTK across a panel of oesophageal cancer 
cell lines. (B) Graph illustrating BTK mRNA expression relative to TE10. (C) Agarose gel electrophoresis of BTK-C PCR products showing presence 
of the BTK-C splice variant in a panel of oesophageal cancer cell lines. (D) Graph illustrating BTK-C mRNA expression relative to KYSE70. (E) Bar 
chart showing decreased cell viability in parental TE8 after transfection with individual siBTK oligonucleotides compared with siAllstar. Normalised 
percentage inhibition = (negative control median − cell viability value) / (negative control median − positive control). (F) Bar chart showing decreased 
cell viability in TE8 with BTK overexpression after transfection with individual siBTK oligonucleotides compared with siAllstar. (G) Western blot 
showing decreased BTK protein expression following transfection with individual siBTK in TE8 with BTK overexpression (lentiviral transduction). 
(H) Bar chart showing decreased cell viability in TE8 after transfection with siBTK-C oligonucleotides. (I) Bar chart showing decreased BTK-C mRNA 
expression following transfection with siBTK-C oligonucleotides.
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at progression. Whole exome sequencing and RNA sequencing 
of serial tumour samples will be undertaken to assess genetic 
determinants of response and resistance to ibrutinib. Sequential 
tumour samples will be evaluated for expression of phosphory-
lated kinases in the ERBB2, AKT and RAS-RAF-MEK-ERK-MYC 
signalling pathways as part of pharmacodynamic biomarker 
assessment. In addition, we will assess the expression of phos-
phorylated proteins that signal downstream of BTK, including 
1-phosphatidylinositol-4,5-bisphosphonate phosphodiesterase 
gamma and protein kinase C. Given that we observed greatest 
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Figure 5 Ibrutinib sensitivity in MYC and/or HER2 amplified oesophageal tumour cell lines. (A) Box plot depicting area under the curve values 
for ibrutinib. Preferential sensitivity to ibrutinib is observed in oesophageal cancer cell lines harbouring MYC and/or ERBB2 amplification. (B) 
Ibrutinib drug sensitivity curves across the panel of oesophageal tumour cell lines. Cell lines that are not MYC or ERBB2 amplified are depicted in 
black, MYC and ERBB2 amplified in purple, MYC amplified alone in blue and ERBB2 amplified alone in red. (C) Western blots showing decreased 
expression of cMYC in MYC amplified KYAE-1 tumour cell line after exposure to 1 µM ibrutinib. (D) Western blot showing decreased expression of 
cMYC in MYC amplified TE8 tumour cell line after exposure to 1 µM ibrutinib. (E) Bar chart showing decreased cell viability in KYAE-1 (MYC and 
ERBB2 amplified) following transfection with siMYC oligonucleotides. (F) Western blot showing decreased protein expression of cMYC following 
transfection of siMYC oligonucleotides in KYAE-1 (MYC and ERBB2 amplified). (G) Cell cycle analysis after 24 and 48 hours of ibrutinib exposure in 
KYAE-1 (MYC and ERBB2 amplified), (H) TE8 (MYC amplified) and (I) JHEsoAd1 (MYC and ERBB2 non-amplified) tumour cell lines. Prolongation of the 
G1 phase is observed with increasing doses of ibrutinib in cell line harbouring MYC amplification. G1 arrest was not observed in JHEsoAd1 (MYC and 
ERBB2 non-amplified) cell line. (J) Western blot showing decreased expression of p-Rb, Rb and cyclin D1 following ibrutinib exposure in KYAE-1 (MYC 
and ERBB2 amplified). (K) Western blot showing decreased expression of cyclin D1 following ibrutinib exposure in TE8 (MYC amplified). (l) Western 
blot showing no change in protein expression of p-Rb, Rb and cyclin D1 following ibrutinib exposure in JHEsoAd1 (MYC and ERBB2 non amplified). 
(M) Bar chart showing the apoptotic cell fraction (percentage of annexin-positive cells) after exposure to increasing doses of ibrutinib (24 and 
48 hours). An increase in apoptosis is observed in KYAE-1 (MYC and ERBB2 amplified) that is not seen in JHEsoAd1 (MYC and ERBB2 non-amplified). 
(N) Western blot showing expression of cleaved PARP1 after ibrutinib exposure in the KYAE-1 (MYC and ERBB2 amplified). Cleaved PARP1 is not seen 
in JHEsoAd1 after ibrutinib exposure (MYC and ERBB2 non-amplified).
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sensitivity to ibrutinib in MYC/ERBB2 coamplified models (4% 
of EAC3) and that ERBB2 amplification only occurs in up to 
11% of ESCC25 compared with up to 32% in EAC,3 it is likely 
that a therapeutic approach utilising ibrutinib will be clinically 
relevant to a larger proportion of patients with EAC within the 
context of this study.
Our aim in providing these data and illustrating its poten-
tial utility is to present testable hypotheses for future work that 
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Figure 6 ERK1/2 is downregulated by ibrutinib. (A) Western blot showing decreased p-BTK protein expression in BTK overexpressed (lentiviral 
transduction) TE8 cell line (MYC amplified) following ibrutinib exposure. (B) Western blot showing decreased p-ERK protein expression in KYAE-1 
tumour cell line (MYC and ERBB2 amplified) and (C) TE8 cell line (MYC amplified) following ibrutinib exposure. (D) Western blots showing that 
ibrutinib exposure results in downregulation of p-MYC S62 and total cMYC in KYAE-1 (MYC and ERBB2 amplified) and (E) TE8 (MYC amplified) 
oesophageal tumour cell lines.
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require orthogonal validation. We recommend that subsequent 
work based on the siRNA analysis incorporates the use of indi-
vidual siRNAs designed to target a gene, CRISPR-Cas9-me-
diated gene targeting or small molecule inhibitors given the 
well-documented off-target effects associated with RNAi 
reagents.51 We are also mindful of the limitations of using tumour 
cell lines in terms of modelling the human disease and would 
recommend that future work relating to oesophageal cancer 
should be validated using patient-derived tumour organoids 
(PDTOs) and xenografts (PDXs). PDXs, where surgically 
resected tumour samples are engrafted directly into immu-
nocompromised mice, offer many advantages over standard 
cell-line xenograft models, including the preservation of the 
molecular heterogeneity frequently observed in human oesoph-
ageal tumours, and represent a genomically characterised 
platform with which to analyse drug sensitivity in relation to 
driver mutations for the purposes of biomarker discovery. In 
addition to commercially available PDX collections, patient-de-
rived in vitro and in vivo models have also been propagated 
through academic collaboration.52 Going forward, it would 
be important to use such platforms to identify the dynamic 
response to ibrutinib in relevant oesophageal cancer PDTOs 
and PDXs as a route to identifying mechanismsof resistance to 
BTK inhibition that might emerge. Finally, candidate predictive 
biomarkers identified from drug screening should be evaluated 
in oesophageal tumour tissues within the context of prospective 
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table 2 Genetic dependencies in oesophageal cancer: Chong et al
Ab 1 Ab dilution 2 Ab dilution company Product code
  BTK 1:1000 (BSA) 1:2000 Rabbit Abcam ab32555
  P BTK (Y223) 1:1000 (BSA) 1:2000 Rabbit Cell Signaling 5082S
  MYC 1:5000 (BSA) 1:5000 Rabbit Abcam ab32072
  P MYC (Ser62) 1:1000 (BSA) 1:5000 Rabbit Cell Signaling 13 748
  PARP 1 1:1000 (Milk) 1:5000 Mouse Santa Cruz sc-8007
  Cyclin D1 1:2000 (BSA) 1:2000 Rabbit Cell Signaling 2922
  P Rb (Ser780) 1:5000 (BSA) 1:5000 Rabbit Cell Signaling 8180
  Total Rb 1:2000 (Milk) 1:5000 Mouse Cell Signaling 9309
  P-ERK (Thr202/Tyr2014) 1:1000 (BSA) 1:5000 Rabbit Cell Signaling 4370
  Total ERK 1:1000 (BSA) 1:5000 Rabbit Cell Signaling 9102
  Actin 1:2000 (milk) 1:10 000 (milk) Mouse Santa Cruz Sc-47778
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clinical studies utilising targeted therapies and correlated with 
clinical outcome.
supplementary tables
All online supplementary tables have been made publicly avail-
able and can be accessed using the following link: https:// doi. 
org/ 10. 5281/ zenodo. 826575.
MAterIAls AnD MetHODs
cell lines
Tumour cell lines were obtained from the American Type 
Culture Collection, European Collection of Cell Cultures and 
Deutsche Sammlung von Mikroorganismen und Zellkulturen, 
and maintained as per the supplier’s instructions. Short tandem 
repeats (STR) geno typing of 10 loci was performed using the 
GenePrint 10 system (Promega) and used to confirm the identity 
of cell lines prior to storage. At monthly intervals, mycoplasma 
testing was carried out using MycoAlert Mycoplasma Detection 
Kit (Lonza).
Array comparative genomic hybridisation
All cell line and tumours were subjected to aCGH (Breakthrough 
Breast Cancer Research Centre) 32K BAC array platform 
and profiled as previously described.27 siRNA screening and 
processing 17 oesophageal cancer cell lines were optimised for 
siRNA screening conditions by titrating cell number and trans-
fection lipid. Each cell line was transfected with a plate-arrayed 
siRNA library targeting 714 kinases and kinase-related genes 
(Dharmacon in a 384-well plate format) as described in Camp-
bell et al.26
Association testing
An MP test was used to identify associations between specific 
features (histotype or driver gene mutation) and sensitivity to 
specific siRNAs. For each kinase we compared the observed 
difference between the median Z score of the interest group 
(mutant, tissue of interest or other grouping variable) and the 
median Z score of the ‘other’ group (wild-type, non-tissue of 
interest or inverse of other grouping variable) to that expected 
based on random permutation.
small molecule kinase inhibitor growth assays
The compound screens comprised an in-house library of 80 small 
molecule inhibitors (0.5, 1, 5, 10, 50, 100, 500 and 1000 nM). 
Five hundred cells were seeded in 384-well plates. Twen-
ty-four hours post seeding, drug treatment was initiated and cells 
were continuously exposed to the drugs (6 days), at which point 
cell viability was estimated using CellTiter-Glo (Promega). Lumi-
nescence values were normalised to the median of the per-plate 
dimethyl sulphoxide (DMSO) negative control wells and the 
dose–response relationships modelled using three-parameter 
logistic regression provided by the drc R package. AUC scores 
are represented as a proportion of the maximum area under 
curve (calculated as: log10(500000) − log10(500)=3).
btK and btK-c Pcr
RNA was extracted from untreated cells using RNeasy Mini 
Kit (Qiagen). One microgram of RNA was converted to cDNA 
using reverse transcriptase with the iScript cDNA synthesis kit 
(BioRad) as per manufacturer’s instructions. The cDNA was 
used to detect BTK or BTK-C with the following primers: BTK 
forward 5'- GGGGTTTGCTCAGACTGTCC-3', BTK-C forward 
5'- AATGAAGGGGTCCTCCACCT-3' and BTK/BTK-C reverse 
5'- AATCACTGCGGCCATAGCTT-3'. PCR was performed 
using Platinum Green Hot Start PCR 2x Master mix (Thermo 
Fisher) as per manufacturer’s instructions.
btK and btK-c real-time Pcr
RNA was extracted and converted to cDNA. Real time PCR was 
carried out using PowerUp SYBR Green Master mix (Thermo 
Fisher) and 20x PrimePCR primers for BTK and Actin (BioRad). 
For BTK-C, the primers used were those described by Eifert et 
al (Genes, Chromosomes and Cancer, 2013) and actin primers 
were forward 5'-CCCTGGCACCCAGCAC-3' and reverse 
5'-GCCGATCCACACGGAGTAC-3'.
reverse transfections and cell viability assay
Fifteen microlitres of each siRNA species were mixed with 
750 µL of optimum and incubated at RT (10 min). Fifty micro-
litres of RNAiMax (Invitrogen) were incubated with 2.5 mL 
optimum (10 min). Two hundred fifty microlitres  of transfection 
mix were added to the siRNA mix and incubated at RT (30 min). 
Of the transfection/siRNA mix, 17.5 µL was plated in triplicate 
in 96-well plate format, then 80 µL cells/well (0.025×106 cells/
mL) were then seeded. After 5 days, 35 µL CellTiter-Glo was 
added per well. The de-convoluted siRNA target sequences used 
are as follows: 
siMYC1 AACGUUAGCUUCACCAACA siMYC2 GGAACU-
AUGACCUCGACUA siMYC3 GAACACACAACGUCUUGGA 
siMYC4 CUACCAGGCUGCGCGCAAA siBTK1 GCUAUG-
GGCUGCCAAAUUU siBTK2 GAAAGCAACUUACCAUGGU 
siBTK3 GGUAAACGAUCAAGGAGUU siBTKC1  GGU UAUU 
GGAU GCCC AUUAUU siBTKC2  GGG AGAG CACA CAGG 
UGAAUU
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Apoptosis assay
Apoptotic cells were identified using an FITC Annexin V Kit 
(BD Bioscience). Cells were plated and treated the following 
day with ibrutinib for 48 or 72 hours, trypsinised, washed in 
phosphate-buffered saline (PBS) and resuspended in 1x Annexin 
binding buffer. Five microlitres of FITC Annexin V and 5 µL 
propidium iodide (PI) and 400 µL of 1x Annexin binding buffer 
were added. Data were analysed on a BD LSRII flow cytometer.
cell cycle assay
Cells were plated and treated the following day with ibrutinib 
for 24 or 48 hours. Cells were trypsinised, washed in PBS and 
fixed in 70% ethanol, then treated with 50 µg/mL RNase A. PI 
was added (50 µg/mL) and data were analysed on a BD LSRII 
flow cytometer.
Western blotting
Cell lysates were separated using 4%–12% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) Bis-Tris 
gel, transferred to nitrocellulose membrane, blocked in 5% milk 
and blotted with antibodies (table 2).
btK overexpression in MYc amplified oesophageal cancer cell 
lines
BTK was overexpressed using a lentiviral vector containing the 
BTK ORF (Source Bioscience). Five micrograms of this plasmid 
with 4 µg psPAX2 packaging plasmid and 1.5 µg pMD2.G enve-
lope plasmid were combined with Lipofectamine 3000 and 
P3000 (Thermo Fisher) and used to transfect 2×1 06 293 T cells.
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